Neurology: cNfL acts as a biomarker for neurodegenerative and survival in patients with Parkinson's disease.

A recent study published in the journal Leading Journal of Neurology aims to determine whether the sensitive biomarker neurocytokine light chain protein () of neuroalist damage in cerebrospinal fluid can reflect the severity of the disease or predict the survival rate of patients with Parkinson's diseaseIn a population-based study queue, the researchers investigated whether the severity, profile, or survival rate of new patients was related to concentrations before and after diagnosisThe second, larger new queue () is used for independent validationThe researchers assessed the relationship between brain pathology and concentration at baseline, year and year using striatum dopamine transporter protein imaging and repeated dispersal flambrasis imagingEarly increases were associated with shorter severity of the severity of all major motor symptoms and olfactory disordersConcentrations above the median during follow-up increased the patient's overall risk of death by a multipleThe higher age and sex adjustment were associated with defects in the intake of striatum dopamine transportproteins and lower fractions in multiple axial burst slateral imagingThis can be seen as a biomarker of the severity of the disease and predicts the patient's survivalCurrent results suggest that concentrations reflect the degree of neurodegenerativeity, which may be important in future clinical trials